hourglass
Loading…
Preparing the latest DD data, styles and content.
53NeutralDD: Sep 04, 2026Analyst: 63
paidPrice at analysis date
USD 4.29 (04/09/2026)
domainMkt cap
$708.88M
pie_chartShares
165M
candlestick_chart52W
$1.01-$5.78
trending_downShort interest
9%
MEDIUMNasdaqHealth Care180 employeesFounded 1998
Verdict: Moderately AttractiveCash-generative single-product specialty pharma (LINZESS, co-promoted with AbbVie). Trades at ~3.3x EV/EBITDA on raised FY26 guidance ($310M+ Adj EBITDA), a ~65% discount to specialty-pharma peers, reflecting the 2027-2030 LINZESS loss-of-exclusivity cliff and a de-risked-to-one pipeline (apraglutide, delayed by FDA-mandated second Phase 3). Base FV ~$5.85 (+36% vs $4.29), driven by NPV of remaining LINZESS profits plus probability-weighted apraglutide option value. Consensus PT $6.23 (+45%) sits just above our base — the delta reflects our more conservative apraglutide probability (35% vs implied ~45% in consensus).
📊 DIANALITICS RESEARCH INDEX
Company & Thesis Assessment
Score /100 — updated 2026-09-04
63
Fin. strength
11
/20 pts
EBITDA/FCF
12
/15 pts
Debt/leverage
12
/15 pts
Stage/business
8
/15 pts
Catalysts
6
/10 pts
Reg. risk
4
/8 pts
Risk/reward
4
/7 pts
Management
2
/5 pts
Sector/macro
2
/3 pts
Compliance
2
/2 pts
💡 Fair Value Estimate — LINZESS NPV + apraglutide rNPV (SotP), cross-checked with EV/EBITDA
Fair value base case
USD 5.85
Range: USD 3.00-USD 7.75
Price at analysis date: USD 4.29 (04/09/2026)
Base upside/downside: +36%
Primary: SotP NPV. LINZESS US = 7-year explicit forecast of Ironwood's ~50% profit share (from 50/50 AbbVie collaboration structure), FY26 base $220M, growth 2026-2028, then 40%/60%/80% erosion 2029/2030/2031, discount rate 10%. LINZESS ex-US = royalty at 5-8% of ex-US net sales. Apraglutide rNPV = 30% probability of approval (post the FDA-mandated confirmatory Phase 3), peak sales $400-500M, 25% net margin to Ironwood, launch 2030, discount 12% risk-adjusted. Net debt uses management's year-end 2026 target of <$300M gross debt less ~$100M cash. Cross-check via EV/EBITDA sets an upper bound but is not used as primary because it ignores the LOE-driven cash-flow cliff. Sensitivity: apraglutide probability is the single largest FV driver. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| LINZESS US NPV (2026-2032) | Profit-share cash $250M FY26 → peak $260M FY28 → erosion 30%/60%/85% FY29-31 (Teva/Mylan generics), disc @ 10%: ~$785M / 165M sh | +4.75 |
| LINZESS ex-US royalty NPV | ~$15-20M/yr royalty, 8-year runway, disc @ 10%: ~$100M / 165M sh | +0.60 |
| Apraglutide rNPV (SBS-IF) | 35% approval prob × $720M NPV (peak $450-500M × 25% margin, launch 2030, disc @ 12%) / 165M sh | +1.55 |
| Net debt (Q4'26E target) | ~$300M gross debt (revolver) − ~$100M cash = $200M net debt / 165M sh | −1.21 |
| Tax NOL / working cap | Residual value of federal & state NOL carryforwards ∼ $27M PV / 165M sh | +0.16 |
| FV base case | Sum: 4.75 + 0.60 + 1.55 − 1.21 + 0.16 = 5.85 | ≈ $5.85 |
Bull
$7.00–$7.50
Probability: 20%
Apraglutide Phase 3 readout positive (50% prob raised), LINZESS ex-US royalty grows on new-market launches, potential BD deal for pipeline diversification, multi-year buyback.
Base
$5.50–$6.25
Probability: 50%
FY26 guidance met, LINZESS grows through 2028, apraglutide Phase 3 on track for 2028-29 readout, orderly deleveraging.
Bear
$2.50–$3.00
Probability: 30%
Apraglutide Phase 3 fails or is materially delayed, LINZESS generic erosion accelerates on off-label prescribing, competitive pressure from Motegrity/Amitiza generics, dividend/buyback off the table.
Methodology: Primary: SotP NPV. LINZESS US = 7-year explicit forecast of Ironwood's ~50% profit share (from 50/50 AbbVie collaboration structure), FY26 base $220M, growth 2026-2028, then 40%/60%/80% erosion 2029/2030/2031, discount rate 10%. LINZESS ex-US = royalty at 5-8% of ex-US net sales. Apraglutide rNPV = 30% probability of approval (post the FDA-mandated confirmatory Phase 3), peak sales $400-500M, 25% net margin to Ironwood, launch 2030, discount 12% risk-adjusted. Net debt uses management's year-end 2026 target of <$300M gross debt less ~$100M cash. Cross-check via EV/EBITDA sets an upper bound but is not used as primary because it ignores the LOE-driven cash-flow cliff. Sensitivity: apraglutide probability is the single largest FV driver. ⚠️ Not investment advice. Not investment advice.
warning
🚨 Loss-of-exclusivity cliff & single-product concentration
LINZESS composition-of-matter patent (U.S. Patent 7,304,036, pediatric exclusivity applied) expires 2027-02-28. Teva generic launch authorized 2029-03-31, Mylan 2030-02-05 (145/290 mcg) and 2030-08-05 (72 mcg). LINZESS accounts for essentially 100% of revenue and profit. Formulation patents extend to early 2030s but do not prevent authorized generic entry per settled litigation. Post-2029 cash flow decline is structural, not cyclical.
warning
🔄 FV reconciliation vs prior report
Fair value lowered from $8.10 (report 2026-07-03) to $5.85 ( −27.8% ). Drivers: (1) FDA required a second confirmatory Phase 3 for apraglutide (STARS-2, site initiations Q2'26) → approval delayed from 2027-28 to 2029-30 and probability of success re-cut from ~55% to 35%, removing ~$2.0/sh of rNPV. (2) Explicit deduction of $200M net debt (−$1.21/sh) after $200M convert repayment in June 2026 — previously netted less cleanly. (3) More conservative LINZESS erosion pace 2029-2031 given the Teva (2029-03-31) and Mylan (2030-02) authorized-generic dates now fully baked in the model. Partial offset: LINZESS US NPV up ~$0.40/sh on FY26 EBITDA guidance raise ($310M+ vs prior $270-280M).
⚠️ Methodology note: IRWD is a single-product specialty pharma with a defined patent cliff — FV built primarily on NPV of LINZESS profit share (Ironwood's ~50% economic share of the AbbVie collaboration in the US + ex-US royalties), plus probability-weighted rNPV of apraglutide (SBS-IF), cross-checked with a low-multiple EV/EBITDA (4.5x forward). EPS-based P/E is misleading because forward earnings decline sharply as R&D re-ramps for apraglutide Phase 3 (STARS-2) and generic erosion begins.
📊 Capital Structure · Short Interest · Buyback & Dilution
🟡 Short Interest
~7-9%
Moderate. Bearish thesis: LOE erosion + apraglutide execution risk. Days-to-cover ~6-8 given average volume 1.84M shs. No dedicated short-seller report identified in last 12 months.
🟡 Share dilution (1Y)
~+1%
Diluted share count ~165M vs ~163M a year ago. Modest equity comp dilution; no primary equity raise. $200M convert repaid in cash June 2026 (no conversion equity impact).
🟢 Buyback / Dividend
None active
No dividend (yield N/A). No repurchase program active. Free cash used to repay convertibles and fund apraglutide Phase 3. Program could resume post-2027 if apraglutide validates.
Short Interest & insider activity — context
Insider Form 4 activity: net sellers over past 3 months. Notable: PFO Ronald Silver sold 127,890 shs at $4.52 (~$578K) under 10b5-1 plan — above the $500K threshold and worth flagging, though scheduled sales pre-arranged. Director Julie McHugh sold 21,571 shs at $3.73 (10b5-1). No open-market discretionary insider buying reported. Man Group PLC held ~$15.7M as recently as mid-2025 (institutional, not insider).
Financial analysis — FY 2024A → FY 2026E
Revenue (FY26E)
$460-485M
Raised guidance
Adj EBITDA (FY26E)
>$310M
Raised guidance
LINZESS US H1'26
$555M
+44% YoY
Gross debt (Q4'26E)
<$300M
Post-convert repay
| Item | FY23A | FY24A | FY25A | FY26E | Guidance FY26 |
|---|---|---|---|---|---|
| Total revenue ($M) | 430 | 428 | 375 | ~475 | $460-485M |
| LINZESS US net sales ($M) | 1,015 | 1,033 | 870 | ~1,175 | $1.15-1.20B |
| Adj EBITDA ($M) | 260 | 240 | 245 | >310 | >$310M |
| GAAP Net income ($M) | 171 | 129 | 147 | ~200 | Not guided |
| Diluted EPS ($) | 1.09 | 0.82 | 0.90 | ~1.20 | Not guided |
| Gross debt ($M) | 620 | 585 | 585 | <300 | Deleveraging |
| Cash ($M) | 85 | 90 | 90 | ~100 | Post-convert repay |
FY23-25 figures approximate from company releases; FY26E from raised guidance issued Q2'26 (Aug 6, 2026). Historical fluctuations reflect the AbbVie collaboration accounting (net vs gross presentation) and one-off items.
| Metric | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|
| Total revenue ($M) | 96 | 92 | 90 | 107 | 113 |
| LINZESS US net sales ($M) | 247 | 232 | 222 | 273 | 282 |
| Adj EBITDA ($M) | 60 | 55 | 50 | 75 | 83 |
| Diluted EPS ($) | 0.19 | 0.15 | 0.13 | 0.28 | 0.31 |
| Cash EoP ($M) | 105 | 135 | 170 | 235 | 79 |
Q2'26 cash drop reflects $200M convert repayment at maturity in June. Collaboration receivable of $113M at quarter-end will convert to cash in Q3.
Financial position and sustainability
Net debt / FY26E EBITDA
~0.6x
FY26E FCF conversion
~80%
Cash runway to apraglutide readout
Ample
Revenue concentration (LINZESS)
~100%
account_tree
Business model — LINZESS cash cow, apraglutide as sole late-stage bet
Single-product cash generator with one late-stage pipeline candidate
Ironwood commercializes LINZESS (linaclotide) in the U.S. in a 50/50 profit-share collaboration with AbbVie since 2012, and receives royalties on international sales from AbbVie. LINZESS is the #1 branded prescription therapy for adult IBS-C and CIC (chronic idiopathic constipation). Q2 2026 US net sales $282.3M (+14% YoY); H1 2026 $555M (+44% YoY) — the acceleration reflects favorable payer mix and pediatric label expansion. Pipeline was deliberately narrowed in April 2025 (IW-3300 for interstitial cystitis discontinued after Phase 2). Apraglutide, a long-acting GLP-2 analog for SBS-IF, is the sole late-stage bet — the FDA required a confirmatory Phase 3 (STARS-2), with site initiations begun Q2 2026, delaying approval to ~2029-2030.
Revenue mix (est. FY26): LINZESS US profit share ~95% / LINZESS ex-US royalty ~5% / Other <1%. Pipeline: apraglutide (Phase 3 in progress) is the only late-stage asset; no early-stage catalysts to speak of. Balance sheet is being aggressively deleveraged ($200M convert repaid June 2026, target <$300M gross debt by year-end).
gavel
Legal, regulatory and risk analysis
LINZESS loss of exclusivity
CRITICALComposition patent expires Feb 2027; authorized generic entry by Teva 2029-03-31, Mylan 2030. Post-2029 revenue trajectory is structurally negative — the entire investment thesis lives or dies on how much cash is harvested pre-cliff and how apraglutide performs.
Apraglutide binary Phase 3
HIGHFDA rejected initial NDA package and required confirmatory Phase 3 (STARS-2). Readout not before 2028-29. Any second failure would essentially remove pipeline optionality and force IRWD into pure liquidation/harvest mode.
Single-product concentration
HIGH~100% of revenue from LINZESS. No commercial diversification, no early-stage pipeline. Any label restriction, safety signal or accelerated generic entry is fully unhedged.
AbbVie collaboration dependency
MODERATEAbbVie controls US commercialization and ex-US licensing. Change in commercial priorities or unfavorable renegotiation at LOE would compress Ironwood's economics disproportionately.
Strong cash generation pre-cliff
POSITIVEFY26E Adj EBITDA >$310M with 80% FCF conversion → roughly $250M/yr of free cash through 2028. Enough to fully fund apraglutide Phase 3 and clear the remaining $300M gross debt by 2028.
Balance sheet deleveraging
POSITIVE$200M convert notes retired at maturity June 2026 (cash). Year-end target <$300M gross debt with net debt/EBITDA <1x — leaves optionality for BD or capital return.
Insider selling (net)
MODERATEPFO sold ~$578K under 10b5-1 (above the $500K disclosure threshold). Director McHugh also sold. Net insider activity is sell-only in 2026 — scheduled but nonetheless a negative signal.
M&A / take-private optionality
POSITIVESub-$1B EV, single strong cash-generating asset, motivated seller pre-LOE — the profile fits a PE take-private or a specialty-pharma bolt-on. Not our base case, but a real optional catalyst.
article
SWOT analysis
Strengths
- +LINZESS is #1 branded therapy in a $2B+ IBS-C/CIC market
- +FY26 Adj EBITDA >$310M, ~80% FCF conversion
- +Balance sheet materially strengthened post $200M convert repayment
- +Trades at ~3.3x EV/EBITDA — deep value on 2026-2028 cash
- +50/50 AbbVie collaboration provides commercial scale without infra cost
Weaknesses
- −~100% revenue concentration in one drug
- −Patent cliff starting Feb 2027; authorized generic entry 2029
- −Pipeline reduced to a single Phase 3 asset after IW-3300 termination
- −Forward earnings expected to decline as R&D re-ramps
- −Net insider selling in 2026 (scheduled 10b5-1 plans)
Opportunities
- →Apraglutide (STARS-2) Phase 3 readout worth $1-2/sh if positive
- →M&A take-out at premium given clean asset profile and sub-$1B EV
- →Multi-year buyback resumption post-2027 if apraglutide de-risks
- →LINZESS pediatric label expansion continues to drive US growth
- →Business-development deals to add pipeline diversification
Threats
- !Apraglutide Phase 3 failure → no post-LOE growth story
- !Accelerated LINZESS generic erosion or off-label prescribing shift
- !Competitive launches (Motegrity/Amitiza generics, novel IBS therapies)
- !Interest-rate / spread environment for the $300M revolver refinancing
- !AbbVie deprioritizing LINZESS given its own Rinvoq/Skyrizi focus
article
Summary by assessment area
🟢 Valuation risk — LOW
- EV/EBITDA fw ~3.3x, ~65% discount to peers
- Base FV $5.00 supports +17% upside
- Consensus PT $6.23 requires apraglutide execution
🔴 Long-term thesis risk — CRITICAL
- LINZESS composition patent expires Feb 2027
- Generic entry 2029-30 → structural cash cliff
- Pipeline reduced to single Phase 3 bet (apraglutide)
🔵 Balance sheet / cash — POSITIVE
- Convert notes retired June 2026 ($200M cash)
- Net debt/EBITDA <1x; ample runway
- M&A/take-private optional catalyst
Sources & Disclaimer
Sources: IRWD Q2 2026 earnings release & call transcript (Aug 6, 2026), 10-Q Q1 2026 (SEC), MarketBeat live quote (last update 2026-09-03), Simply Wall St, GuruFocus, BioSpace, Ironwood investor site, DrugPatentWatch, Ironwood-Teva/Mylan patent settlement filings. Market data — last verified close 2026-09-03: IRWD $4.29 (−2.72%), market cap $708.88M, 52W $1.01–$5.78, shares outstanding ~165M. Short interest ~7-9% (est.). This document is for informational purposes only and does not constitute financial or investment advice.